The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sargsyan V.D.

National Medical Research Center for Therapy and Preventive Medicine

Safaryan A.S.

National Medical Research Center for Therapy and Preventive Medicine

The importance of omega fatty acids for the prevention of cardiovascular disease

Authors:

Sargsyan V.D., Safaryan A.S.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2021;24(7): 90‑95

DOI: 10.17116/profmed20212407190

Read: 4332 times

Download PDF (RU)
Contact the author
Table of contents

THE IMPORTANCE OF OMEGA FATTY ACIDS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
THE IMPORTANCE OF OMEGA FATTY ACIDS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE

To cite this article:

Sargsyan VD, Safaryan AS. The importance of omega fatty acids for the prevention of cardiovascular disease. Russian Journal of Preventive Medicine. 2021;24(7):90‑95. (In Russ.)
https://doi.org/10.17116/profmed20212407190

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Inno­vative approach for cardiovascular risk predicting by machine learning methods using. Russian Journal of Preventive Medi­cine. 2025;(7):36-42
Age-related features of como­rbidity in the presence of chro­nic non-communicable diseases risk factors: obesity, arte­rial hype­rtension, hype­rtriglyceridemia. Russian Journal of Preventive Medi­cine. 2025;(11):45-51
Abstract:

Among patients with risk factors for cardiovascular disease receiving drug treatment for primary or secondary prevention, the incidence of cardiovascular events remains high. It was revealed that such patients have an increased level of triglycerides (TG), which serves as an independent marker of an increased risk of ischemic events. Several strategies have been used to reduce TG levels including lifestyle changes such as dietary changes (including fish and seafood in the diet) and pharmacological interventions. Among medicines the omega-3-polyunsaturated fatty acids (ω-3-PUFA) occupy a special place: usually a mixture of eicosapentaenoic and docosahexaenoic acids. This review evaluates ω-3-PUFAs depending on the composition and source of their preparation.

Keywords:

omega-3-polyunsaturated fatty acids
eicosapentaenoic acid
docosahexaenoic acid
hypertriglyceridemia
prevention of cardiovascular diseases

Authors:

Sargsyan V.D.

National Medical Research Center for Therapy and Preventive Medicine

Safaryan A.S.

National Medical Research Center for Therapy and Preventive Medicine

Received:

10.03.2021

Accepted:

30.03.2021

Close metadata

References:

  1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group.ESC 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016;37(29):2315-2381. 3 
  2. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
  3. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988;8(6):737-741.  https://doi.org/10.1161/01.atv.8.6.737
  4. Lewis H, Kuller, MD, DrPH Nutrition, Lipids, and Cardiovascular Disease. Nutrition Reviews. 2006;64(2):15-25. 
  5. Pahwa R, Jialal I. Atherosclerosis. Treasure Island (FL): StatPearls Publishing; 2021. Accessed May 20, 2021. https://www.ncbi.nlm.nih.gov/books/NBK507799/
  6. Barquera S, Pedroza-Tobias A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, Moran AE. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328-338. 
  7. Berkow SE, Barnard N. Vegetarian diets and weight status. Nutr Rev. 2006; 64(4):175-188.  https://doi.org/10.1111/j.1753-4887.2006.tb00200.x
  8. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM. JAMA. 2006; 295(6):655-66.  https://doi.org/10.1001/jama.295.6.655
  9. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J ClinNutr. 1975;28:958-966. 
  10. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D’Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-1357.
  11. Nambi V, Bhatt DL. Primary prevention of atherosclerosis: time to take a selfie? J Am Coll Cardiol. 2017;70:2992-2994.
  12. Vaduganathan M, Venkataramani AS, Bhatt DL. Moving toward global primordial prevention in cardiovascular disease: the heart of the matter. J Am Coll Cardiol. 2015;66:1535-1537.
  13. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-1504.
  14. Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2015;36:774-776. 
  15. Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A, Tenenbaum A.Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the Bezafibrate Infarction Prevention Study and Registry. Circ Cardiovasc Qual Outcomes. 2016;9:100-108. 
  16. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;103:3019-3027.
  17. Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2018 September 17 (Epub ahead of print).
  18. Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018; 7(15):e008740-e008740.
  19. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-T, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen M-L, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S, ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal. 2016;37:2315-2381. https://doi.org/10.1093/eurheartj/ehw106
  20. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450-458. 
  21. Spector A, Kim HY. Discovery of Essential Fatty Acids. J Lipid Res. 2014; 56:11-21.  https://doi.org/10.1194/jlr.R055095
  22. Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol. 2006;98(4A):50-60. 
  23. Rosenberg IH. Fish — food to calm the heart. N Engl J Med. 2002;346(15): 1102-1103.
  24. Kornsteiner M, Singer I, Elmadfa I. Very low n-3 long-chain polyunsaturated fatty acid status in Austrian vegetarians and vegans. Ann Nutr Metab. 2008;52:37-47.  https://doi.org/10.1159/000118629
  25. Fokkema MR, Brouwer DA, Hasperhoven MB, Martini IA, Muskiet FA. Short-term supplementation of low-dose gamma-linolenic acid (GLA), alpha-linolenic acid (ALA), or GLA plus ALA does not augment LCP omega 3 status of Dutch vegans to an appreciable extent. Prostaglandins Leukot Essent Fat Acids. 2000;63:287-292.  https://doi.org/10.1054/plef.2000.0216
  26. Davis BC, Kris-Etherton PM. Achieving optimal essential fatty acid status in vegetarians: Current knowledge and practical implications. Am J Clin Nutr. 2003;78:640-646.  https://doi.org/10.1093/ajcn/78.3.640S
  27. Simopoulos AP. Human requirement for N-3 polyunsaturated fatty acids. Poult Sci. 2000;79:961-970.  https://doi.org/10.1093/ps/79.7.961
  28. Emken EA, Adlof RO, Duval SM, Nelson GJ. Effect of dietary arachidonic acid on metabolism of deuterated linoleic acid by adult male subjects. Lipids. 1998;33:471-480.  https://doi.org/10.1007/s11745-998-0230-x
  29. Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int J Vitam Nutr Res. 1998;68:159-173. 
  30. Bang HO, Dyerberg J, Sinclair HM, The composition of the Eskimo food in north western Greenland. Am J Clin Nutr. 1980;33(12):2657-2661. https://doi.org/10.1093/ajcn/33.12.2657
  31. Feskens EJ, Kromhout D. Epidemiologic studies on Eskimos and fish intake. Ann NY Acad Sci. 1993;683:9-15.  https://doi.org/10.1111/j.1749-6632.1993.tb35688.x
  32. Keys A, Kimura N. Diets of middle-aged farmers in Japan. Amer J clin Nutr. 1970;23:212. 
  33. Kromhout D. N-3 fatty acids and coronary heart disease: epidemiology from Eskimos to Western populations. J Intern Med Suppl. 1989;731:47-51.  https://doi.org/10.1111/j.1365-2796.1989.tb01435.x
  34. Martinez-Gonzalez MA, Bes-Rastrollo M, Serra-Majem L, Lairon D, Estruch R, Trichopoulou A.Mediterranean food pattern and the primary prevention of chronic disease: recent developments. Nutr Rev. 2009;67(suppl 1): 111-116. 
  35. Zhang B, Xiong K, Cai J, Ma A. Fish Consumption and Coronary Heart Disease: A Meta-Analysis. Nutrients. 2020;12(8):2278. https://doi.org/10.3390/nu12082278
  36. Matsuyama S, Sawada N, Tomata Y, Zhang S, Goto A, Yamaji T, Iwasaki M, Inoue M, Tsuji I, Tsugane S; Japan Public Health Center-based Prospective Study Group. Association between adherence to the Japanese diet and all-cause and cause-specific mortality: The Japan Public Health Center-based Prospective Study. Eur J Nutr. 2021:60:1327-1336. https://doi.org/10.1007/s00394-020-02330-0
  37. Erkkila AT, Lichtenstein AH, Mozaffarian D, Herrington DM. Fish intake is associated with a reduced progression of raronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr. 2004; 80(3):626-632. 
  38. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;130(7):554-562. 
  39. Zhao W, Tang H, Yang X, Luo X, Wang X, Shao C, He J. Fish consumption and stroke risk: A meta-analysis of prospective cohort studies. J Stroke Cerebrovasc Dis. 2019;28:604-611. 
  40. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(5 suppl):1645S-1654S
  41. Hayrapetyan L. AHA recommends omega-3 fatty acids to reduce triglyceride levels. Medvestnik. Portal of the Russian doctor; 2019. https://medvestnik.ru/content/news/AHA-rekomenduet-jirnye-kisloty-omega-3-dlya-snijeniya-urovnya-trigliceridov.html
  42. FDA Drug Approval Package. Omacor (Omega-3-Acid Ethyl Esters) Capsules. Silver Spring: U.S. Food and Drug Administration; 2004. Accessed May 20, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-654_Omacor.cfm
  43. FDA announces qualified health claims for omega-3 fatty acids. Press release. Natural Products Insider; 2004. Accessed May 20, 2021. https://www.naturalproductsinsider.com/regulatory/fda-announces-qualified-health-claim-omega-3-fatty-acids
  44. Tutel’yan VA, Baturin AK, Vasil’ev AV, Vrzhesinskaya OA, Vysockij VG, Gapparov MM, Kodencova VM, Kon’ IYa, Kravchenko LV, Kuvaeva IB, Kulakova SN, Lashneva NV, Mazo VK, Sokolov AI, Soto SX, Spirichev VB, Hotimchenko SA, Shatrov GN, Sheveleva SA, Eller KI, Onishchenko GG, Petuhov AI, Kukes VG, Suhanov BP, Tyukavkina NA, Samylina IA, Grigor’ev AI, Petrov RV, Martynov AI, Bagirova VL, Devichenskij VM, Semenov BF, Mihajlova NA, Shabrov AV, Dadali VA, Tkachenko EI, Lesiovskaya EE, Bykov VA, Sokol’skaya TA, Kolhir VK, Skal’nyj AV, Nuzhnyj VP, Bulaev VM, Skal’naya MG. Rekomenduemye urovni potrebleniya pishchevyh i biologicheski aktivnyh veshchestv. Metodicheskie rekomendacii MR 2.3.1.1915-04. M.: Federal’nyj centr Gossanepidnadzora Minzdrava Rossii; 2004. Accessed May 20, 2021. (In Russ.). https://mbionika.ru/d/mr2.3.1.1915-04rekomenduyemyyeurovnipotrebleniyapishchevykhibiologicheskiaktivnykhveshchest.pdf
  45. Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008;87(6):1981-1990.
  46. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman M, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). European Society of Cardiology (ESC) European Atherosclerosis Society (EAS) ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3-46. 
  47. The Gruppo Italiano per lo Studio del la Sopravvivenzanell’ Infarto Miocardio (GISSI)-Prevenzione Trial on fish oil and vitamin E supplementation in myocardial infarction survivors. Curr Cardiol Rep. 2000;2(5):445-451.  https://doi.org/10.1007/s11886-000-0059-5
  48. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators.Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-1098.
  49. The ORIGIN Trial Investigators. n−3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309-318. 
  50. The ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379:1540-1550.
  51. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R; Omega-3 Treatment Trialists’ Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3:225-234. 
  52. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, Summerbell CD, Worthington HV, Song F, Hooper L. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Systematic Review. Intervention Version published: 29 February 2020 see what’s new.  https://doi.org/10.1002/14651858.CD003177.pub5
  53. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22. 
  54. Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia. Independent Data Monitoring Committee has recommended to discontinue the trial as Epanova is unlikely to demonstrate a benefit to patients. AstraZeneca; 2020. Accessed May 20, 2021. https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html
  55. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019;140:673-691 
  56. Huang T, Li K, Asimi S, Chen Q, Li D. Effect of vitamin B-12 and n-3 polyunsaturated fatty acids on plasma homocysteine, ferritin, C-reaction protein, and other cardiovascular risk factors: A randomized controlled trial. Asia Pac J Clin Nutr. 2015;24:403-411. 
  57. Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: An updated meta-analysis of seventeen cohort studies. Public Heal Nutr. 2011;15:725-737. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.